Evaluating the Effectiveness of Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Metastatic Colorectal Cancer in Practice: Protocol for the Prospective PROACTIF Phase IV Registry Study in Fra

Date publication

novembre 2021

Journal

Cardiovascular and interventional radiology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MANFREDI Sylvain

Tous les auteurs :
Garin E, Pinaquy JB, Bailly C, Sengel C, Mariano-Goulart D, Edeline J, Blanc JF, Bouvier A, Tordo J, Rode A, Becker S, Sefrioui D, de Baere T, Somma C, Mastier C, Goupil J, Chevallier P, Regnault H, Vibert E, Manfredi S, Vicaut E, Patel B, Boucher E, Guiu B,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34796373

Résumé

Recently, selective internal radiation therapy using yttrium-90 (Y90) glass microspheres (TheraSphere™) was approved for reimbursement by health authorities in France. The PROACTIF study aims to gather data on effectiveness, patient quality of life, and safety with use of Y90 glass microspheres in real-world clinical settings in France.

Mots clés

Hepatocellular carcinoma, Intrahepatic cholangiocarcinoma, Liver metastatic colorectal cancer, Selective internal radiation therapy, Yttrium-90

Référence

Cardiovasc Intervent Radiol. 2021 Nov 18;: